What is Adma Biologics Inc Quarterly Revenue?

Adma Biologics Inc Quarterly Revenue Adma Biologics Inc Jun-2026 Quarterly Revenue is $124 Million which is growth of 2.0% YoY.

What is Adma Biologics Inc Quarterly Net Profit?

Adma Biologics Inc Quarterly Net Profit Adma Biologics Inc Jun-2026 Quarterly Net Profit is $38 Million which is growth of 10.5% YoY.

What is Adma Biologics Inc Annual Revenue?

Adma Biologics Inc Annual Revenue Adma Biologics Inc Dec-2025 Annual Revenue is $510 Million which is growth of 19.6% YoY.

What is Adma Biologics Inc Annual Net Profit?

Adma Biologics Inc Annual Net Profit Adma Biologics Inc Dec-2025 Annual Net Profit is $147 Million which is growth of -25.7% YoY.

What is Adma Biologics Inc Total Shareholders Fund?

Adma Biologics Inc Total Shareholders Fund Adma Biologics Inc Dec-2025 Total Shareholders Fund is $477 Million which is growth of 36.8% YoY.

What is Adma Biologics Inc Total Assets?

Adma Biologics Inc Total Assets Adma Biologics Inc Dec-2025 Total Assets is $624 Million which is growth of 27.7% YoY.

What is Adma Biologics Inc Book Value Per Share?

Adma Biologics Inc Book Value Per Share Adma Biologics Inc Book Value Per Share is $2 which is growth of 9.2% YoY.

What is Adma Biologics Inc ROE?

Adma Biologics Inc ROE Adma Biologics Inc ROE is 0% which is growth of 0% YoY.

What is Adma Biologics Inc Cash From Operating Activity?

Adma Biologics Inc Cash From Operating Activity Adma Biologics Inc Dec-2025 Cash From Operating Activity is $50 Million which is growth of -57.5% YoY.

What is Adma Biologics Inc Net Cash Flow?

Adma Biologics Inc Net Cash Flow Adma Biologics Inc Dec-2025 Net Cash Flow is $-16 Million which is growth of -130.0% YoY.

Adma Biologics Inc

XNAS: ADMA

Await Turnaround

Download real time

-0.04(-0.39%)

50.44% Fall from 52W High

3.0M

XNAS Volume

XNAS 07 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Adma Biologics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Adma Biologics Inc share price target, revenues, EPS, net income and more

Adma Biologics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Adma Biologics Inc Jun-2026 Quarterly Revenue is $124 Million which is growth of 2.0% YoY.
POSITIVE
Quarterly Net Profit Adma Biologics Inc Jun-2026 Quarterly Net Profit is $38 Million which is growth of 10.5% YoY.

Adma Biologics Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
SR_Q Operating Rev.	124.4	114.5	139.2	134.2	122	114.8	117.6	119.8	107.2	81.9	73.9	67.3	60.1
CostOfRevenue_Q Cost Of Rev.	38.1	33.7	50.4	58.6	54.8	53.7	54.2	60.2	49.7	42.8	42.8	42.6	43.4
GrossProfit_Q Gross Profit	86.3	80.8	88.8	75.6	67.2	61.1	63.3	59.7	57.5	39.1	31.1	24.7	16.7
OEXPNS_Q Operating Exp. ⌄	33.8	30.5	26.1	24.6	24.4	26.2	25	20	18.3	17.3	16.9	16	17.2
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	26.7	26.7	23.5	21.8	22.2	24.1	23.3	18.6	16.6	15.6	15.5	14.7	14.3
ResearchAndDevlopmentExpenses_Q RnD Exp.	6	2.6	1.4	1.5	1	0.8	0.4	0.4	0.6	0.5	0.5	0.6	1.4
OP_Q Operating Profit	52.4	50.3	62.8	51	42.8	34.9	38.3	39.6	39.2	21.8	14.2	8.7	-0.5
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses ⌄	-2.2	-1	-1.1	-1.3	-1.4	-1.4	-2.3	-2.8	-3.3	-3.4	-5.6	-6	-5.9
Others_Q Other Interest Earned	1.2	1.1	0.5	0.4	0.4	0.6	0.6	0.7	0.5	0.4	0.6	0.4	0.4
IntExpNonOperating_Q Interest Exp. Non Operating	3.4	2.1	1.6	1.7	1.8	2	2.9	3.5	3.8	3.8	6.2	6.4	6.3
PBT_Q Profit Before Tax	50.2	57.1	61.6	47.5	40.1	33.5	34.7	36.8	35.9	18.4	-17.6	2.6	-6.4
TAX_Q Tax	12.4	11.8	12.2	11.1	5.9	6.6	-77.2	0.8	3.8	0.6	-	-	-
NICommonStockholders_Q Net Income Common Stockholders ⌄	37.8	45.3	49.4	36.4	34.2	26.9	111.9	35.9	32.1	17.8	-17.6	2.6	-6.4
NP_Q Net Profit	37.8	45.3	49.4	36.4	34.2	26.9	111.9	35.9	32.1	17.8	-17.6	2.6	-6.4
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	37.8	45.3	49.4	36.4	34.2	26.9	111.9	35.9	32.1	17.8	-17.6	2.6	-6.4
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	37.8	45.3	49.4	36.4	34.2	26.9	111.9	35.9	32.1	17.8	-17.6	2.6	-6.4
EPS_Q Basic EPS	0.2	0.2	0.2	0.2	0.1	0.1	0.5	0.2	0.1	0.1	-0.1	0	-0
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	0.2	0.2	0.2	0.2	0.1	0.1	0.5	0.2	0.1	0.1	0	0	-0
SHARE_Q Number Of Shares End	228.2	236.1	238	238.6	241.5	237.8	236.5	234.6	232.4	228.9	226	225.3	222.7
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	37.8	45.3	49.4	36.4	34.2	26.9	111.9	35.9	32.1	17.8	-17.6	2.6	-6.4
NormalizedIncome_Q Normalized Income	37.8	39	49.4	38.1	35.2	26.9	111.9	35.9	32.1	17.8	8.5	2.6	-6.4
InterestIncome_Q Interest Income	1.2	1.1	0.5	0.4	0.4	0.6	0.6	0.7	0.5	0.4	0.6	0.4	0.4
INT_Q Interest	3.4	2.1	1.6	1.7	1.8	2	2.9	3.5	3.8	3.8	6.2	6.4	6.3
NetInterestIncome_Q Net Interest Income	-2.2	-1	-1.1	-1.3	-1.4	-1.4	-2.3	-2.8	-3.3	-3.4	-5.6	-6	-5.9
EBIT_Q EBIT	53.7	59.2	63.2	49.2	41.9	35.4	37.6	40.3	39.6	22.2	-11.4	9	-0.1
EBITDA_Q EBITDA	55.4	61.1	65.3	51.2	44	37.4	39.5	42.2	41.7	24.3	-9.3	11.1	2
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	36.4	32	48.4	56.6	52.7	51.8	52.3	58.3	47.8	40.9	40.9	40.7	41.5
ReconciledDepreciation_Q Reconciled Depr.	1.8	1.8	2.1	2	2.1	2	1.9	1.9	2.1	2.1	2.1	2.1	2.1
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	37.8	45.3	49.4	36.4	34.2	26.9	111.9	35.9	32.1	17.8	-17.6	2.6	-6.4
NormalizedEBITDA_Q Normalized EBITDA	55.4	53.1	65.3	53.4	45.2	37.4	39.5	42.2	41.7	24.3	16.9	11.1	2

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Adma Biologics Inc competitor comparison and performance snapshot within industry

Adma Biologics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Adma Biologics Inc Dec-2025 Annual Revenue is $510 Million which is growth of 19.6% YoY.
NEGATIVE
Annual Net Profit Adma Biologics Inc Dec-2025 Annual Net Profit is $147 Million which is growth of -25.7% YoY.

Adma Biologics Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
SR_A Total Rev. Ann. ⌄	49%	64.6%		510.2	426.5	258.2	154.1	80.9	42.2	29.4	17	22.8	10.7	7.2
TotalOperatingRevenues_A Operating Rev. Ann.	49%	64.6%	512.3	510.2	426.5	258.2	154.1	80.9	42.2	29.4	17	15.8	10.7	7.2
CostOfRevenue_A Cost Of Rev. Ann.	22.3%	28.8%	180.8	217.4	206.9	169.3	118.8	79.8	61.3	39.5	42.2	29.2	6.4	4.3
GrossProfit_A Gross Profit Ann.	102.4%	-	331.5	292.8	219.6	88.9	35.3	1.2	-19.1	-10.2	-25.2	-6.4	4.3	2.9
OEXPNS_A Operating Exp. Ann.	10.7%	17.2%	115	101.3	80.6	67.3	74.6	59.6	45.8	31.3	35.1	32.1	21.6	18.4
OP_A Operating Profit Ann.	-	-	216.5	191.4	139	21.6	-39.4	-58.4	-64.9	-41.4	-60.3	-38.5	-17.3	-15.5
NetNonOperIntIncExp_A Net Non Operations Interest Incuding Expenses Ann, ⌄	-	-	-5.6	-5.2	-11.8	-23.4	-19.2	-13	-11.7	-8.2	-5.3	-3.2	-2.2	-1.8
Others_A Other Interest Earned Ann.	-	44.7%	3.2	1.9	2.1	1.6	0	0	0.3	0.8	0.2	0.1	0.1	0
IntExpNonOperating_A Interest Exp. Non Operating Ann.	-28.3%	-10%	8.8	7.1	13.9	25	19.3	13.1	12	9	5.5	3.3	2.2	1.8
OtherExpenses_A Other Exp. Ann.	-	-		-3.6	-1.4	-26.5	-7.3	-0.3	0.9	1.3	-0.1	-2.1		-0.7
PBT_A PBT Ann.	-	-	216.5	182.7	125.7	-28.2	-65.9	-71.7	-75.8	-48.3	-65.7	-43.8	-19.5	-18
TAX_A Tax Ann.	-	-	47.5	35.7	-72	-	-	-	-	-	-	-	-	-
NICommonStockholders_A Net Income Common Stockholders Ann. ⌄	-	-	169	146.9	197.7	-28.2	-65.9	-71.7	-75.8	-48.3	-65.7	-43.8	-19.5	-18
NP_A Net Profit Ann.	-	-	169	146.9	197.7	-28.2	-65.9	-71.7	-75.8	-48.3	-65.7	-43.8	-19.5	-18
NIIncludingNoncontrollingInterests_A Net Income Including Non controlling Interests Ann.	-	-	169	146.9	197.7	-28.2	-65.9	-71.7	-75.8	-48.3	-65.7	-43.8	-19.5	-18
DilutedNIAvailtoComStockholders_A Diluted NI Avail to Com Stockholders Ann.	-	-	169	146.9	197.7	-28.2	-65.9	-71.7	-75.8	-48.3	-65.7	-43.8	-19.5	-18
EPS_A EPS Ann.	-	-		0.6	0.9	-0.1	-0.3	-0.5	-0.9	-0.9	-1.5	-1.9	-1.6	-1.7
DilutedEPS_A Diluted EPS Ann.	-	-		0.6	0.8	-0.1	-0.3	-0.5	-0.9	-0.9	-1.5	-1.9	-1.6	-1.7
SHARE_Q Number Of Shares End	5.5%	19.7%		238	236.5	226	202.9	181.3	96.7	59.4	46.4	45.3	12.9	10.4
TotalExpenses_A Total Exp. Ann.	18.1%	24.4%		318.7	287.5	236.6	193.4	139.3	107.1	70.8	77.3	61.2	28	22.7
NIContinuingDiscontinuedOper_A Net Income Continuing Discontinued Operations Ann.	-	-	169	146.9	197.7	-28.2	-65.9	-71.7	-75.8	-48.3	-65.7	-43.8	-19.5	-18
NormalizedIncome_A Normalized Income Ann.	-	-	164.3	149.6	198.7	-2.1	-59.2	-71.7	-76.7	-49.8	-65.7	-41.7	-19.5	-17.3
InterestIncome_A Interest Income Ann.	-	44.7%	3.2	1.9	2.1	1.6	0	0	0.3	0.8	0.2	0.1	0.1	0
INT_A Interest Ann.	-28.3%	-10%	8.8	7.1	13.9	25	19.3	13.1	12	9	5.5	3.3	2.2	1.8
EBITDA_A EBITDA Ann.	-	-	233	197.9	147.7	5.1	-39.5	-53.1	-59.8	-36	-56.8	-37.8	-16.8	-15.7
ReconciledCostOfRevenue_A Reconciled Cost Of Rev. Ann.	23.1%	29.2%	173.3	209.5	199.2	161.7	112.4	75	58.1	37.1	39.6	27.7	6.4	4.3
ReconciledDepreciation_A Reconciled Depr. Ann.	4.5%	15.7%	7.7	8.1	8	8.3	7.1	5.5	3.9	3.3	3.5	2.7	0.5	0.5
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	169	146.9	197.7	-28.2	-65.9	-71.7	-75.8	-48.3	-65.7	-43.8	-19.5	-18
NormalizedEBITDA_A Normalized EBITDA Ann.	-	-	227.2	201.2	148.9	31.3	-32.8	-53.1	-60.8	-37.6	-56.8	-35.7	-16.8	-15

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

19.6%

2Y CAGR

40.6%

3Y CAGR

49%

5Y CAGR

64.6%

7Y CAGR

62.6%

10Y CAGR

53.1%

Total Revenue Annual growth is lower than historical averages.

Net Profit Ann.

1Y CHG

-25.7%

Net Profit Annual is falling faster than historical averages.

Operating Exp. Ann.

1Y CHG

25.7%

2Y CAGR

22.7%

3Y CAGR

10.7%

5Y CAGR

17.2%

7Y CAGR

16.3%

10Y CAGR

18.6%

Operating Expenses Annual Cr growth is higher than historical averages.

Adma Biologics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund Adma Biologics Inc Dec-2025 Total Shareholders Fund is $477 Million which is growth of 36.8% YoY.
POSITIVE
Total Assets Adma Biologics Inc Dec-2025 Total Assets is $624 Million which is growth of 27.7% YoY.

Adma Biologics Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
TA_A Total Assets Ann. ⌄	21.4%	24.6%	624.2	488.7	329.2	348.5	276.3	207.7	127.1	88.9	108	23.7	23.7
CA_A Total Current Assets Ann.	19.9%	24.9%	466.5	331.4	257	270.4	208.7	153.7	85.8	44.5	63.2	21.7	21.3
CashEquivalentsShortTermInvestments_A Cash Equivalents and Short Term Investments Ann.	0.4%	9.4%	87.6	103.2	51.4	86.5	51.1	55.9	26.8	22.8	43.1	15.3	16.8
Receivables_A Change In Account Receivables Ann.	117%	64.4%	158.4	50	27.4	15.5	28.6	13.2	3.5	1.4	3.9	1	0.9
Inventories_A Inventories Ann.	8.1%	20.4%	206.5	170.2	172.9	163.3	124.7	81.5	53.1	18.6	12.6	5	3.5
OtherCurrentAssets_A Other Current Assets Ann.	13.7%	19.3%	7.5	8	5.3	5.1	4.3	3.1	2.5	1.8	2.1	-	-
TotalNonCurrentAssets_A Total Non Current Assets Ann.	26.4%	24%	157.7	157.3	72.2	78.1	67.5	53.9	41.3	44.4	44.9	2	2.4
NetPPE_A Net PPE Ann.	1.4%	9.3%	71.7	63.3	63.5	68.8	58.2	45.9	31.7	30.1	30.5	2	2.4
InvestmentsAndAdvances_A Investments & Advances Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
OtherNonCurrentAssets_A Other Non Current Assets Ann.	21.5%	32.6%	8.6	5.7	4.7	4.8	4.1	2.1	2.8	6.7	6	0	0
TotalLiabilitiesNetMinorityInterest_A Total Liabilities Net Minority Interest Ann. ⌄	-9.2%	4.2%	146.9	139.7	194	196.5	135.1	119.4	100.9	69.1	67.7	28.1	22.9
CL_A Total Current Liabilities Ann.	20.9%	28.3%	69.5	55.5	49.8	39.3	30.4	20	14	9.6	9.4	11.2	4.2
PayablesAndAccruedExpenses_A Payables & Accrued Exp.s Ann.	17.3%	24.8%	58.8	52.3	45.7	36.4	28.6	19.4	13.7	9.5	9.2	5	4.1
CurrentDebtCapLeaseObligation_A Current Debt Cap Lease Obligation Ann.	63%	57.7%	3.9	1.2	1	0.9	0.6	0.4	0.2	0	-	6.1	0
CurrentDeferredLiabilities_Q Current Deferred Liabilities	-	-	-	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2
OtherCurrentLiabilities_A Other Current Liabilities Ann.	55.7%	-	6.8	1.9	2.9	1.8	1	-	-	-	0.1	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann.	-21%	-4.9%	77.4	84.1	144.2	157.2	104.7	99.5	86.9	59.5	58.3	16.9	18.7
LongTermDebtAndCapitalLeaseObligation_Q LT Debt & Capital Lease Obligation	-20.9%	-4.8%	76	80.9	140.4	153.5	102.3	97.3	84.5	44.2	43	14.1	15.7
TradeandOtherPayablesNonCurrent_A Trade & Other Payables Non Current Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalDeferredCreditsAndOtherNonCurrentLiabilities_A Total Deferred Credits & Other Non Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	46.4%	40.1%	477.3	349	135.2	152	141.2	88.3	26.2	19.8	40.3	-4.5	0.8
EQCAP_A Equity Share Capital Ann.	46.4%	40.1%	477.3	349	135.2	152	141.2	88.3	26.2	19.8	40.3	-4.5	0.8
CapitalStock_A Capital Stock Ann.	-	-	0	0	0	0	0	0	0
RetainedEarnings_A Retained Earnings Ann.	-	-	-161.7	-308.6	-506.3	-478	-412.1	-340.5	-264.7	-216.4	-150.7	-106.9	-87.4
GainsLossesNotAffectingRetainedEarnings_A Gains Losses Not Affecting Retained Earnings Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalCapitalization_A Total Capitalization Ann.	22.9%	24.7%	546.7	421.4	265.8	294.8	236	181.2	109.4	63.9	83.3	9.7	16.5
TangibleAssets_A Tangible Assets Ann.	47.5%	41.9%	473.2	345	131.2	147.4	135.9	82.3	19.5	12.2	32	-4.5	0.8
WC_A Working Capital Ann.	19.8%	24.3%	397	275.9	207.2	231.1	178.4	133.8	71.8	34.9	53.7	10.4	17.1
InvestedCapital_A Invested Capital Ann.	23.1%	24.8%	549.5	421.4	265.8	294.8	236	181.2	109.4	63.9	83.3	15.8	16.5
TangibleBookValue_A Tangible Book Value Ann.	47.5%	41.9%	473.2	345	131.2	147.4	135.9	82.3	19.5	12.2	32	-4.5	0.8
Borrowings_A Borrowings Ann.	-19.7%	-3.9%	79.9	82.1	141.4	154.4	102.9	97.7	84.7	44.2	43	20.3	15.7
NetDebt_A Net Debt Ann.	-	-	-	-	79.2	56.3	43.8	37.1	56.5	21.3	-	10.3	5.2
ShareIssued_A Share Issued Ann.	2.6%	18%	239.8	236.6	226.1	221.8	195.8	104.9	59.3	46.4	45.3	12.9	10.7
SHARE_Q Number Of Shares End	5.5%	19.7%	238	236.5	226	202.9	181.3	96.7	59.4	46.4	45.3	12.9	10.4

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Assets Ann.

1Y CHG

27.7%

2Y CAGR

37.7%

3Y CAGR

21.4%

5Y CAGR

24.6%

7Y CAGR

32.1%

10Y CAGR

38.7%

Total Assets Annual growth is stable compared to historical averages.

Total Current Liabilities Ann.

1Y CHG

25.2%

2Y CAGR

18.1%

3Y CAGR

20.9%

5Y CAGR

28.3%

7Y CAGR

32.7%

10Y CAGR

32.4%

Total Current Liabilities Annual Cr growth is stable compared to historical averages.

Total ShareHolders Funds Ann.

1Y CHG

36.8%

2Y CAGR

87.9%

3Y CAGR

46.4%

5Y CAGR

40.1%

7Y CAGR

57.6%

10Y CAGR

89.5%

Total ShareHolders Funds Annual growth is lower than historical averages.

Adma Biologics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Book Value Per Share Adma Biologics Inc Book Value Per Share is $2 which is growth of 9.2% YoY.
NEUTRAL
ROE Adma Biologics Inc ROE is 0% which is growth of 0% YoY.

Adma Biologics Inc, Ratios, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
ROA_A RoA Ann. %	-	-	-	48.34%	-8.33%	-21.10%	-29.61%	-45.25%	-44.71%	-66.78%	-66.45%	-82.34%	-70.55%
ROE_A ROE Ann. %	-	-	-	81.65%	-19.67%	-44.96%	-62.46%	-132.38%	-210.08%	-218.77%	-243.95%	-	-526.23%
ROIC_Q ROIC %	-	-	-	29.4	-4.2	-2.3	-5.9	-9.1	-6.9	-23	-18.5	-	-22.3
OPMPCT_A OPM Ann. %	-	-	37.53%	32.59%	8.38%	-25.55%	-72.12%	-153.75%	-141.14%	-354.95%	-169.00%	-162.56%	-216.14%
NBTO_A Inventory Turnover Ratio Ann.	-	-	-	1.2	1	0.8	0.8	0.9	1.1	2.7	3.3	1.5	1.7
ASETTO_A Asset Turnover Ann. %	-	-	-	1	0.8	0.5	0.3	0.3	0.3	0.2	0.4	0.5	0.3
WCTO_A Working Capital Turnover Ann.	22.9%	34.1%	1.3	1.6	1.3	0.7	0.5	0.3	0.4	0.5	0.4	1	0.4
QuickRatio_A Quick Ratio Ann.	-	-	-	2.8	1.6	2.6	2.6	3.5	2.2	2.5	5	1.5	4.2
CRATIO_A Current Ratio Ann.	-	-	-	6	5.2	6.9	6.9	7.7	6.1	4.6	6.7	1.9	5.1
IC_A Interest Coverage Ratio Ann.	-	-	-	10	-0.1	-2.4	-4.5	-5.3	-4.4	-10.9	-12.3	-7.7	-8.8
LTDE_A LT Debt To Equity Ann.	-	-	-	0.2	1	1	0.7	1.1	3.2	2.2	1.1	-	19.1

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Adma Biologics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity Adma Biologics Inc Dec-2025 Cash From Operating Activity is $50 Million which is growth of -57.5% YoY.
NEGATIVE
Net Cash Flow Adma Biologics Inc Dec-2025 Net Cash Flow is $-16 Million which is growth of -130.0% YoY.

Adma Biologics Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
CFO_A Cash from Operating Act. Ann. ⌄	-	-	50.4	118.7	8.8	-59.5	-112.4	-102	-76.2	-62.7	-37.3	-18.3	-15.4
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	146.9	197.7	-28.2	-65.9	-71.7	-75.8	-48.3	-65.7	-43.8	-19.5	-18
DepreciationAmortizationDepletion_A Depreciation Amortization Depletion Ann.	4.5%	15.7%	8.1	8	8.3	7.1	5.5	3.9	3.3	3.5	2.7	0.5	0.5
DepreciationAndAmortization_A Depreciation And Amortization Ann.	4.5%	15.7%	8.1	8	8.3	7.1	5.5	3.9	3.3	3.5	2.7	0.5	0.5
DeferredTax_A Deferred Tax Ann.	-	-	11	-84.3	-	-	-	-	-	-	-	-	-
DeferredIncomeTax_A Deferred Income Tax Ann.	-	-	11	-84.3	-	-	-	-	-	-	-	-	-
EmployeesStockOptions_A ESOPs Ann.	56.7%	47.1%	20	13.6	6.2	5.2	3.5	2.9	2.7	2.2	1.6	1.3	1.7
OtherNonCashItems_A Other Non Cash Items Ann.	-51.6%	-17.8%	0.6	0.8	6.3	5.3	1.8	1.6	1	1	0.6	0.5	0.4
ChangeInWorkingCapital_A Change In Working Capital Ann.	-	-	-139.6	-18.5	-10.1	-18.3	-51.7	-33.8	-33.5	-3.7	-0.3	-1	-0.7
ChangeInReceivables_A Change In Receivables Ann.	-	-	-108.4	-22.6	-11.9	13.1	-15.3	-9.8	-2.1	2.5	-2.9	-0.1	-0.5
ChangeInInventory_A Change In Inventory Ann.	-	-	-36.2	2.7	-9.6	-38.6	-43.2	-28.5	-34.7	-6	0.6	-1.6	-1.7
ChangePayablesAccruedExpense_A Change Payables Accrued Expense Ann.	-3.3%	7.2%	7.5	5.2	11.4	8.3	9.7	5.3	4.1	0.4	3.4	0.9
ChangeInOtherCurrentAssets_A Change In Other Current Assets Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ChangeInOtherCurrentLiabilities_A Change In Other Current Liabilities Ann.	-	-	-1.2	-1.1	-0.8	-0.5	0.2	-0.1	-0.2	0.2	-0	-	-
ChangeInOtherWorkingCapital_A Change In Other Working Capital Ann.	-	-	-	-	-	-	-	-	-	-	-0.5	-0	1.6
CFI_A Cash from Investing Act. Ann. ⌄	-	-	-21.9	-8.6	-5	-13.9	-13.5	-12.7	-3.8	-2.1	15.2	0.9	-1.7
NetPPEPurchaseAndSale_A Net PPE Purchase & Sale Ann.	-	-	-22.6	-8.2	-4.8	-13.9	-13.5	-12.7	-3.8	-2.1	-2.7	-0.1	-0
PurchaseOfPPE_A Purchase Of PPE Ann.	-	-	-22.6	-8.2	-4.8	-13.9	-13.5	-12.7	-3.8	-2.1	-2.7	-0.1	-0
NetBusinessPurchaseAndSale_A Net Business Purchase & Sale Ann.	-	-	-	-	-	-	-	-	-		12.5	-	-
PurchaseOfBusiness_A Purchase Of Business Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
PurchaseOfInvestment_A Purchase Of Investment Ann.	-	-	-	-	-	-	-	-	-	-	-	-15.7	-1.7
SaleOfInvestment_A Sale Of Investment Ann.	-	-	-	-	-	-	-	-	-		5.4	16.7	-
NetOtherInvestingChanges_A Net Other Investing Changes Ann.	-	-	1	-	-	-	-	-	-	-	-	-	-
CFA_A Cash from Financing Act. Ann. ⌄	-	-	-44	-58.3	-39	108.9	121.1	143.9	80	42.9	60.8	16.8	10.4
NetIssuancePaymentsOfDebt_A Net Issuance Payments Of Debt Ann.	-	-	-0.9	-60	-23.6	51.7	-0	13.5	42.5	-0	25	4	0.7
NetLongTermDebtIssuance_A Net Long Term Debt Issuance Ann.	-	-	-0.9	-60	-23.6	51.7	-0	13.5	42.5	-0	25	4	0.7
NetShortTermDebtIssuance_A Net ST Debt Issuance Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetCommonStockIssuance_A Net Common Stock Issuance Ann.	-	-	-31.9			64.7	121.1	131.2	48.4	42.9	39.2	14.1	10.3
CommonStockIssuance_A Common Stock Issuance Ann.	-	-	-			64.7	121.1	131.2	48.4	42.9	39.2	14.1	10.3
CommonStockPayments_A Common Stock Payments Ann.	-	-	-31.9	-	-	-	-	-	-	-	-	-	-
dividend_1Y_actual Dividend 1year	-	-
DividendPerShare_A Dividend Per Share Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetOtherFinancingCharges_A Net Other Financing Charges Ann.	-	-	-14.1	-5.8	-16.5	-7.7	-0.1	-0.8	-10.9	-	-3.4	-1.3	-0.6
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	0.4%	9.4%	87.6	103.2	51.4	86.5	51.1	55.9	26.8	26.8	48.6	9.9	10.4
NetIncDecInCashAndCashEquivalents_A Net Increase In Cash Plus Cash Eqv.s Ann.	-	-	-15.5	51.8	-35.2	35.4	-4.8	29.2		-21.9	38.7	-0.5	-6.8
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	26.4%	31%	103.2	51.4	86.5	51.1	55.9	26.8	26.8	48.6	9.9	10.4	17.2
IncomeTaxPaidSupplementalData_A Income Tax Paid Supplemental Data Ann.	-	-	19.7	9.4	-	-	-	-	-	-	-	-	-
InterestPaidSupplementalData_A Interest Paid Supplemental Data Ann.	-13.2%	-2.4%	9.1	10.7	18.1	13.9	11.2	10.3	8.1	4.4	2.3	1.5	1.3
CapitalExpenditure_A Capex Ann.	-	-	-22.9	-8.6	-5	-13.9	-13.5	-12.7	-3.8	-2.1	-2.7	-0.1	-0
IssuanceOfCapitalStock_A Issuance Of Capital Stock Ann.	-	-	-			64.7	121.1	131.2	48.4	42.9	39.2	14.1	10.3
IssuanceOfDebt_A Issuance Of Debt Ann.	-11.6%	30.7%	105		135	151.8		27.5	72.5		45	4	16
RepaymentOfDebt_A Repayment Of Debt Ann.	-	-	-105.9	-60	-158.6	-100	-0	-14	-30	-0	-20	-0	-15.3
RepurchaseOfCapitalStock_A Repurchase Of Capital Stock Ann.	-	-	-31.9	-	-	-	-	-	-	-	-	-	-
FreeCashFlow_A Free Cash Flow Ann.	-	-	27.5	110.1	3.8	-73.4	-125.9	-114.7	-80	-64.8	-40	-18.3	-15.4

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Cash from Operating Act. Ann.

1Y CHG

-57.5%

2Y CAGR

139.3%

Cash from Operating Activity Annual is falling faster than historical averages.

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow

50.44% Fall from 52W High

Adma Biologics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

Adma Biologics Inc - Forecaster

Forecaster Analyst Estimates for Adma Biologics Inc share price target, revenues, EPS, net income and more

Adma Biologics Inc - Earnings Report - Quarterly Results

Adma Biologics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue Adma Biologics Inc Jun-2026 Quarterly Revenue is $124 Million which is growth of 2.0% YoY.

Quarterly Net Profit Adma Biologics Inc Jun-2026 Quarterly Net Profit is $38 Million which is growth of 10.5% YoY.

Adma Biologics Inc - Competitors/Peers

Adma Biologics Inc competitor comparison and performance snapshot within industry

Adma Biologics Inc - Earnings Report - Annual Results

Adma Biologics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Annual Revenue Adma Biologics Inc Dec-2025 Annual Revenue is $510 Million which is growth of 19.6% YoY.

Annual Net Profit Adma Biologics Inc Dec-2025 Annual Net Profit is $147 Million which is growth of -25.7% YoY.

Adma Biologics Inc - Balance Sheet

Adma Biologics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund Adma Biologics Inc Dec-2025 Total Shareholders Fund is $477 Million which is growth of 36.8% YoY.

Total Assets Adma Biologics Inc Dec-2025 Total Assets is $624 Million which is growth of 27.7% YoY.

Adma Biologics Inc - Ratios

Adma Biologics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Book Value Per Share Adma Biologics Inc Book Value Per Share is $2 which is growth of 9.2% YoY.

ROE Adma Biologics Inc ROE is 0% which is growth of 0% YoY.

Adma Biologics Inc - Cash Flow

Adma Biologics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Cash From Operating Activity Adma Biologics Inc Dec-2025 Cash From Operating Activity is $50 Million which is growth of -57.5% YoY.

Net Cash Flow Adma Biologics Inc Dec-2025 Net Cash Flow is $-16 Million which is growth of -130.0% YoY.